Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gary Treece

Endocrinology, Diabetes & Metabolism Yakima, WA Medical Doctor

NPI 1447269857 CMS profile 155878

209 S 12Th Ave, Yakima, WA 98902

Open in the dashboard

General payments

$806

45 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gary Treece of Yakima, WA is reported in the CMS Open Payments database as having received $806 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $80 3
2023 General $35 2
2022 General $139 4
2021 General $208 13
2020 General $198 13
2019 General $147 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Treece
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Gary Treece were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Gary Treece Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $147 $494 $123–$2,253 $163
2020 $198 $335 $85–$1,841 $114
2021 $208 $398 $88–$1,981 $132
2022 $139 $364 $88–$1,568 $149
2023 $35 $420 $113–$1,614 $160
2024 $80 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $86 5 payments
  2. Abbott Laboratories $78 3 payments
  3. AstraZeneca Pharmaceuticals LP $71 5 payments
  4. Amgen Inc. $67 4 payments
  5. Dexcom, Inc. $64 4 payments
  6. Sanofi-Aventis U.S. LLC $59 4 payments
  7. Electromed, Inc. $57 1 payment
  8. Novo Nordisk Inc $47 3 payments
  9. Pfizer Inc. $40 1 payment
  10. GlaxoSmithKline, LLC. $40 2 payments
  11. Other $197 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $752 43 payments
  2. Education $54 2 payments
Products named General payments · program years 2019–2024
  1. JARDIANCE $86 5 payments
  2. FreeStyle Libre 2 $60 2 payments
  3. SMARTVEST $57 1 payment
  4. BYDUREON $40 3 payments
  5. XTANDI $40 1 payment
  6. TRELEGY ELLIPTA $40 2 payments
  7. EVENITY $36 2 payments
  8. Prolia $36 2 payments
  9. Ozempic $35 2 payments
  10. DEXCOM CGM $32 2 payments
  11. Other $461 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

159

Median for Internal Medicine: 777

Drug cost

$2,253

Median for Internal Medicine: $73,373

Branded share of claims

12.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 83 $1,255
Methimazole Generic 36 $450
Metformin Hcl Er Metformin Hcl Brand 20 $369
Alendronate Sodium Generic 20 $179

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTANDI
  • PFIZER INC. $40
$40 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $23
$23 — —
TEPEZZA
  • Amgen Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record